Shanghai Refreshgene Technology Co., Ltd.
Shanghai Refreshgene Technology Co., Ltd.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | Recruiting | Phase 1 / Phase 2 | 2024-11-14 | NCT06141460 | |
| The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR) | PDR - Proliferative Diabetic Retinopathy | Recruiting | Early phase 1 | 2024-05-14 | NCT06412224 |